Floatz logo

Irinotecan

Male Breast Cancer

University of California, IrvineSmall moleculePhase 2Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Male Breast Cancer cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
University of Washington
Phase 2BBB
Cyclophosphamide
Wake Forest University Health Sciences
Phase 2BBB
Cediranib
University of Chicago
Phase 2BB
TAMOXIFEN
Jose Pablo Leone
Phase 3BB

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →